February batch of EMA/CHMP new drug approval recommendations

25 February 2022

Following its February meetings, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for six novel new medicines, as well as two biosimilars.

The CHMP gave a positive opinion for Kimmtrak (tebentafusp), from Immunocore (Nasdaq: IMCR), for the treatment of uveal melanoma, a rare type of eye cancer. Kimmtrak was reviewed under the EMA’s accelerated assessment program. The CHMP based its recommendation on data from a randomized Phase III pivotal study and a supportive study. The study showed that Kimmtrak prolonged patients’ lives: the median overall survival was 21.7 months for patients receiving tebentafusp and 16 months for patients in the control group.

VBI Vaccines’ (Nasdaq: VBIV) PreHevbri (hepatitis B vaccine [recombinant, adsorbed]) was granted a positive opinion for the active immunization against hepatitis B virus infection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK